Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 999

1.

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.

Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR.

J Immunol. 2003 Jun 1;170(11):5636-43.

2.

Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.

Boyaka PN, Ohmura M, Fujihashi K, Koga T, Yamamoto M, Kweon MN, Takeda Y, Jackson RJ, Kiyono H, Yuki Y, McGhee JR.

J Immunol. 2003 Jan 1;170(1):454-62.

4.

Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens.

Duverger A, Jackson RJ, van Ginkel FW, Fischer R, Tafaro A, Leppla SH, Fujihashi K, Kiyono H, McGhee JR, Boyaka PN.

J Immunol. 2006 Feb 1;176(3):1776-83.

5.

A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.

Gorantala J, Grover S, Goel D, Rahi A, Jayadev Magani SK, Chandra S, Bhatnagar R.

Vaccine. 2011 Jun 15;29(27):4521-33. doi: 10.1016/j.vaccine.2011.03.082.

PMID:
21504775
8.

IL-12 is an effective adjuvant for induction of mucosal immunity.

Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR.

J Immunol. 1999 Jan 1;162(1):122-8.

9.

Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.

Hagiwara Y, McGhee JR, Fujihashi K, Kobayashi R, Yoshino N, Kataoka K, Etani Y, Kweon MN, Tamura S, Kurata T, Takeda Y, Kiyono H, Fujihashi K.

J Immunol. 2003 Feb 15;170(4):1754-62.

10.

Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.

Bento D, Staats HF, Gonçalves T, Borges O.

Eur J Pharm Biopharm. 2015 Jun;93:149-64. doi: 10.1016/j.ejpb.2015.03.024.

PMID:
25818119
12.

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.

Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR Jr.

Infect Immun. 2007 Aug;75(8):4020-9.

13.

Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity.

Boyaka PN, Marinaro M, Jackson RJ, van Ginkel FW, Cormet-Boyaka E, Kirk KL, Kensil CR, McGhee JR.

J Immunol. 2001 Feb 15;166(4):2283-90.

14.

Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.

Sloat BR, Shaker DS, Le UM, Cui Z.

FEMS Immunol Med Microbiol. 2008 Mar;52(2):169-79. doi: 10.1111/j.1574-695X.2007.00347.x.

15.

Oral vaccine models: multiple delivery systems employing tetanus toxoid.

Jackson RJ, Staats HF, Xu-Amano J, Takahashi I, Kiyono H, Hudson ME, Gilley RM, Chatfield SN, McGhee JR.

Ann N Y Acad Sci. 1994 Aug 15;730:217-34.

PMID:
8080173
16.

A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Gwinn WM, Johnson BT, Kirwan SM, Sobel AE, Abraham SN, Gunn MD, Staats HF.

Vaccine. 2013 Mar 1;31(11):1480-9. doi: 10.1016/j.vaccine.2013.01.012.

17.
18.

Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues.

Imaoka K, Miller CJ, Kubota M, McChesney MB, Lohman B, Yamamoto M, Fujihashi K, Someya K, Honda M, McGhee JR, Kiyono H.

J Immunol. 1998 Dec 1;161(11):5952-8.

19.

Nasal cholera toxin elicits IL-5 and IL-5 receptor alpha-chain expressing B-1a B cells for innate mucosal IgA antibody responses.

Kataoka K, Fujihashi K, Sekine S, Fukuiwa T, Kobayashi R, Suzuki H, Nagata H, Takatsu K, Shizukuishi S, McGhee JR, Fujihashi K.

J Immunol. 2007 May 15;178(10):6058-65.

20.
Items per page

Supplemental Content

Support Center